Literature DB >> 30610500

Could propranolol be beneficial in adult cerebral cavernous malformations?

Caroline Apra1,2,3, Chloé Dumot4,5, Pierre Bourdillon6,4, Isabelle Pelissou-Guyotat4,5.   

Abstract

Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.

Entities:  

Keywords:  Beta-blocker; Cavernomas; Cavernous angiomas; Cavernous haemangiomas; Cavernous malformations

Mesh:

Substances:

Year:  2019        PMID: 30610500     DOI: 10.1007/s10143-018-01074-0

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  4 in total

1.  Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations.

Authors:  Susanna M Zuurbier; Charlotte R Hickman; Leon A Rinkel; Rebecca Berg; Ulrich Sure; Rustam Al-Shahi Salman
Journal:  Stroke       Date:  2022-04-12       Impact factor: 10.170

2.  The Activation of Endothelial Cells Relies on a Ferroptosis-Like Mechanism: Novel Perspectives in Management of Angiogenesis and Cancer Therapy.

Authors:  Filipa Lopes-Coelho; Filipa Martins; Ana Hipólito; Cindy Mendes; Catarina O Sequeira; Rita F Pires; António M Almeida; Vasco D B Bonifácio; Sofia A Pereira; Jacinta Serpa
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

3.  Inflammation and neutrophil extracellular traps in cerebral cavernous malformation.

Authors:  Anthony C Y Yau; Maria Ascencion Globisch; Favour Chinyere Onyeogaziri; Lei L Conze; Ross Smith; Suvi Jauhiainen; Monica Corada; Fabrizio Orsenigo; Hua Huang; Melanie Herre; Anna-Karin Olsson; Matteo Malinverno; Veronica Sundell; Behnam Rezai Jahromi; Mika Niemelä; Aki Laakso; Cecilia Garlanda; Alberto Mantovani; Maria Grazia Lampugnani; Elisabetta Dejana; Peetra U Magnusson
Journal:  Cell Mol Life Sci       Date:  2022-03-25       Impact factor: 9.207

4.  Clinical, neuroradiological and genetic findings in a cohort of patients with multiple Cerebral Cavernous Malformations.

Authors:  Silvia Lanfranconi; Lorenzo Piergallini; Dario Ronchi; Gloria Valcamonica; Giorgio Conte; Elena Marazzi; Giulia Manenti; Giulio Andrea Bertani; Marco Locatelli; Fabio Triulzi; Nereo Bresolin; Elisa Scola; Giacomo Pietro Comi
Journal:  Metab Brain Dis       Date:  2021-08-06       Impact factor: 3.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.